Patient-Reported Outcomes (PROs) from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory Follicular Lymphoma (FL)

被引：0
|
作者：
Cartron, Gillaume [1 ]
Garcia-Sancho, Alejandro Martin [2 ]
Reguera, Juan Luis [3 ]
Dahiya, Saurabh [4 ]
Guo, Shien [5 ]
Shi, Ling [5 ]
Eliason, Laurie [6 ]
Kumar, Jinender [6 ]
Farazi, Thalia [7 ]
Fasan, Omotayo [6 ]
Izutsu, Koji [8 ]
机构：
[1] Montpellier Univ Hosp Ctr, Clin Hematol Dept, Montpellier, France
[2] Univ Salamanca, Hosp Univ Salamanca, IBSAL, CIBERONC, Salamanca, Spain
[3] Univ Seville, Dept Hematol, Univ Hosp Virgen Rocio IBIS, Seville, Spain
[4] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therap, Palo Alto, CA USA
[5] Evidera, Bethesda, MD USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Bristol Myers Squibb, San Francisco, CA USA
[8] Natl Canc Ctr, Tokyo, Japan
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180175
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting.
    Godwin, John E.
    Mattar, Bassam Ibrahim
    Maris, Michael B.
    Bachier, Carlos R.
    Stevens, Don A.
    Hoda, Daanish
    Varela, Juan Carlos
    Cherry, Mohamad
    Fanning, Suzanne R.
    Essell, James H.
    Yimer, Habte Aragaw
    Courtright, Jay G.
    Sharman, Jeff Porter
    Trede, Nikolaus S.
    Youssef, Marina
    Lymp, James
    Shaughnessy, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study
    Gordon, Leo I.
    Liu, Fei Fei
    Braverman, Julia
    Hoda, Daanish
    Ghosh, Nilanjan
    Hamadani, Mehdi
    Hildebrandt, Gerhard C.
    Peng, Lily
    Guo, Shien
    Shi, Ling
    Sehgal, Alison
    HAEMATOLOGICA, 2024, 109 (03) : 857 - 866
  • [33] Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001
    Patrick, Donald L.
    Powers, Annette
    Parisi, Monika
    Kim, Yeonhee
    Garcia, Jacob
    Dehner, Christine
    Maloney, David G.
    BLOOD, 2019, 134
  • [34] Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Linhares, Yuliya
    Freytes, Cesar
    Cherry, Mohamad
    Bachier, Carlos
    Maris, Michael
    Hoda, Daanish
    Varela, Juan C.
    Bellomo, Courtney
    Cross, Scott
    Essell, James
    Fanning, Suzanne
    Terebelo, Howard
    Yimer, Habte
    Courtright, Jay
    Sharman, Jeff P.
    Kostic, Ana
    Vedal, Min
    Ogasawara, Ken
    Avilion, Ariel
    Espinola, Ricardo
    Yuan, Brenda
    Mattar, Bassam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S514 - S515
  • [35] Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)
    Abramson, Jeremy S.
    Palomba, M. Lia
    Gordon, Leo I.
    Lunning, Matthew A.
    Wang, Michael
    Arnason, Jon E.
    Purev, Enkhtsetseg
    Maloney, David G.
    Andreadis, Charalambos
    Sehgal, Alison R.
    Solomon, Scott R.
    Ghosh, Nilanjan
    Kostic, Ana
    Kim, Yeonhee
    Ogasawara, Ken
    Dehner, Christine
    Siddiqi, Tanya
    BLOOD, 2021, 138
  • [36] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
    Chong, Geoffrey
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Villasboas, Jose C.
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Tucker, David
    Walewski, Jan
    Song, Yuqin
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Luminari, Stefano
    Mayer, Laura Magnano
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jingxian
    Uppala, Amulya
    Shariff, Saleem
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Kim, Tae Min
    CANCER RESEARCH, 2024, 84 (07)
  • [37] TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).
    Patrick, Donald L.
    Chung, Karen C.
    Kim, Yeonhee
    Garcia, Jacob
    Dehner, Christine
    Maloney, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] EXPOSURE RESPONSE (E-R) RELATIONSHIPS OF LISOCABTAGENE MARALEUCEL (LISO-CEL) MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
    Chen, Y.
    Balasubramanian, N.
    Cummings, J.
    Lin, H.
    Ou, S.
    Tuazon, S.
    Perna, S.
    Ogasawara, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S87 - S87
  • [39] Impact of lisocabtagene maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: TRANSCEND NHL 001 (NCT02631044)
    Patrick, D.
    Powers, A.
    Jun, M. Parisi
    Kim, Y.
    Garcia, J.
    Dehner, C.
    Maloney, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 220 - 221
  • [40] PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL
    Patrick, D.
    Matza, L.
    Kim, Y.
    Garcia, J.
    Dehner, C.
    Chung, K. C.
    VALUE IN HEALTH, 2019, 22 : S106 - S106
12345